Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2011

View Archived Issues

Yale University scientists synthesize the aglycon of lomaiviticin A, a promising anticancer agent

Acacia Pharma completes phase I APD-515 trial for xerostomia in advanced cancer

Medivir begins phase Ia trial of HCV polymerase inhibitor TMC-649128

Bombesin BB2 receptor antagonist 77427 shows promise in preclinical models of asthma

Gap junction alpha-1 protein is a marker of prognosis in prostate cancer

First-in-class antibiotic RNPA-1000 inhibits bacterial turnover of RNA

Genotype of polymorphic SLC6A4 gene variants modulates effects of cocaine in vitro

Endoribonuclease Dicer is a potential target for geographic atrophy

New neuraminidase inhibitors claimed at University of British Columbia

AtheroNova advances preclinical evaluation of agents for atherosclerosis

Astellas Pharma withdraws MAA for darexaban in Japan

Adventrx to acquire SynthRx and purified poloxamer-188 for sickle cell disease

SYGNIS Pharma licenses European patent rights to AX-200

Crofelemer is safe and efficacious in phase II trial in adults with watery diarrhea

Lymphoseek phase III trial in breast cancer and melanoma reaches accrual objective

Australian scientists claim novel inhibitors of neuraminidase

Apricus licenses Vitaros to Neopharm in Israel and Palestinian territories

Alkermes reports phase II data on ALKS-37 in opioid-induced bowel dysfunction

Lundbeck donates certain rights regarding Lu-AE58479 to NINDS

New inhibitors claimed of MEKK 5

FDA accepts Acurox NDA filing and grants priority review

Sanofi-aventis to acquire Genzyme

Treatment begins in phase III trial of rHuPH20-delivered MabThera in NHL

FDA requests additional development activities to support approval of Adventrx's ANX-514

Raptor Pharma reopens enrollment in phase III DR Cysteamine trial in nephropathic cystinosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...